Indeed, the m6A epitranscriptomemachinery recently emerged as a novel drug target, with initial effortfocused on the FTO enzyme.22Insilico-based screening allowed the identification of ligandsof the METTL3-METTL14-WTAP complex that served as activators of thecomplex23 or inhibitors of METTL3.24 Notably, a nanomolar ligand of METTL3, STM2457,showed strong anticancer activity in cell lines and in vivo models of AML together with the ability to decrease m6A levels andmodulate translation.25 No inhibitors ofthe YTHDF or YTHDC proteins have been still identified. This evidence concerns the gene METTL3 and acute myeloid leukemia.